 | Review waiting, please be patient.
This may take 2 months or more, since drafts are reviewed in no specific order. There are 4,340 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Submission declined on 13 April 2026 by Superboilles (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
This draft has been resubmitted and is currently awaiting re-review. |  |
Submission declined on 19 February 2026 by ChrysGalley (talk). This draft reads like an advertisement. Wikipedia is an encyclopedia, not a platform for promotion or marketing. Drafts that are exclusively promotional may be deleted without notice.
Declined by ChrysGalley 3 months ago.Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page. Rewrite the draft to remove:
Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject. If you have a conflict of interest (e.g. you are the subject, an employee, or a relative) or are being paid to edit, you must disclose this to comply with Wikipedia's Terms of Use. | |
This draft reads like an advertisement. Wikipedia is an encyclopedia, not a platform for promotion or marketing. Drafts that are exclusively promotional may be deleted without notice.
Declined by Bonadea 3 months ago.Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page. Rewrite the draft to remove:
Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject. If you have a conflict of interest (e.g. you are the subject, an employee, or a relative) or are being paid to edit, you must disclose this to comply with Wikipedia's Terms of Use. | |
Comment: It is still very much in promotional language rather than that of an encyclopedia. For example "used by research laboratories worldwide" is not what an encyclopedia will say. The aspiration of an artificial cardiac device is what a company promotion would say, not an encyclopedia.If you have a conflict of interest under WP:COI then for important transparency reasons this needs to be declared fully. ChrysGalley (talk) 10:38, 19 February 2026 (UTC)
Company type | Private |
|---|---|
| Industry | Bioengineering |
| Founded | 02/01/2019 |
| Founder | |
Key people | |
| Products | 3D Bioprinters and Biomaterials |
Number of employees | ~10 |
| Website | https://www.tissuelabs.com/ |
TissueLabs is a Swiss biotechnology company focused on tissue engineering and biofabrication. Headquartered in Bellinzona, Ticino, Switzerland, the company develops 3D bioprinters and tissue-specific biomaterials for use in laboratory research applications including drug testing, disease modeling, and cell culture.[1][2][3]
History
editFounding
editTissueLabs was founded in January 2019 in Brazil by Gabriel Liguori and Emerson Moretto. The company originated from the IPEN-Cietec incubator at the University of São Paulo and raised approximately $1.6 million in seed funding during its initial phase of development.[1] Liguori, Liguori, a medical doctor and researcher with a doctorate in cardiovascular regenerative medicine from the University of Groningen, had previously been named to the Forbes 30 Under 30 list in 2018[4] and to the MIT Technology Review Innovators Under 35 list in 2020.[5]
In 2021, TissueLabs relocated its headquarters to Switzerland, initially based in Lugano before establishing operations in Bellinzona, citing proximity to European biotech and research networks.[1]
Early development
editDuring its early development, TissueLabs focused on laboratory tools for tissue engineering research. In 2019, the company introduced MatriXpec, a line of tissue-specific hydrogels derived from decellularized extracellular matrix, developed for use in three-dimensional cell culture and bioprinting. By 2020, formulations had been developed for tissue types including myocardium, lung, liver, kidney, and cartilage.[6]
Also in 2020, TissueLabs introduced TissueStart, an extrusion-based 3D bioprinter designed for academic and laboratory use.[1]
In early 2020, during the COVID-19 pandemic, TissueLabs developed MatriWell, an in vitro system combining a cell culture insert with lung-derived hydrogels to model aspects of lung epithelium. The system was made available at no cost for research use in studies of SARS-CoV-2 infection in pulmonary cells.[7] MatriWell was subsequently used in peer-reviewed research published in 2023 examining three-dimensional models for respiratory disease investigation.[8]
Growth
editIn 2021, TissueLabs introduced TissueRay, an MSLA-based 3D bioprinter. The system was presented at the annual congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS).[2]
In 2023, TissueLabs closed a pre-seed financing round of $800,000, led by Mergus Ventures, with participation from MIT Angels and other investors. The funds supported the establishment of a biofabrication facility in Bellinzona, which began operations in early 2024.[9]
In 2024, TissueLabs was selected to participate in the Venture Leaders Biotech program, a Swiss initiative supporting early-stage biotechnology companies. In 2025, TissueLabs introduced TissuePro, a 3D bioprinter with five independent extrusion heads designed for more complex tissue engineering applications.[10][11][3] The company was also included in the Top 100 Startups to Watch list published by Pequenas Empresas & Grandes Negócios (PEGN) that year.[12]
Research direction
editAccording to statements by the company and its founder, TissueLabs is pursuing long-term research into the development of a bioartificial heart[13] using patient-derived cells. In a 2021 interview, Liguori stated that clinical trials for such a device could require an additional 10–15 years of research and development.[4][3]
References
edit- 1 2 3 4 Listek, Vanesa (2021-10-16). "Bioprinting Startup TissueLabs Moves HQ from Brazil to Switzerland". 3DPrint.com. Retrieved 2026-04-01.
- 1 2 Listek, Vanesa (2021-12-02). "New Masked SLA Bioprinter Revealed by TissueLabs". 3DPrint.com. Retrieved 2026-04-01.
- 1 2 3 Abirascid, Emil (2026-04-27). "From patient to pioneer: the entrepreneur revolutionising organ transplants". Startupbusiness.it. Retrieved 2026-05-15.
- 1 2 Riga, Matheus (2021-07-01). "Healthtech brasileira está no caminho para viabilizar impressão em 3D de órgãos humanos". Forbes Brasil (in Brazilian Portuguese). Retrieved 2026-04-01.
- ↑ "Gabriel Liguori". MIT Technology Review Innovators Under 35. Retrieved 2026-04-01.
- ↑ "Estas empresas vão mudar a forma como cuidamos da nossa saúde". Época Negócios (in Brazilian Portuguese). 2022-08-24. Retrieved 2026-04-01.
- ↑ "TissueLabs: New 3D Printed Platform Free to Researchers Studying COVID-19". 3DPrint.com. 2020. Retrieved 2026-04-01.
- ↑ Seixas, Maria Luiza; Bartolomeo, Cynthia Silva; Lemes, Robertha; Nicoliche, Tiago; Okuda, Liria Hiromi; Martins, Leonardo; Ureshino, Rodrigo; Prado, Carla Maximo; Liguori, Tácia Tavares Aquinas; Liguori, Gabriel Romero; Stilhano, Roberta Sessa (2023-09-01). "Disruptive 3D in vitro models for respiratory disease investigation: A state-of-the-art approach focused on SARS-CoV-2 infection". Biomaterials and Biosystems. 11: 100082. doi:10.1016/j.bbiosy.2023.100082. ISSN 2666-5344. PMC 10391659. PMID 37534107.
{{cite journal}}: CS1 maint: article number as page number (link) - ↑ "TissueLabs begins biofabrication activities in Bellinzona". Greater Zurich Area. 2024-03-25. Retrieved 2026-04-01.
- ↑ Duran, Paloma (2025-06-12). "TissueLabs Scales Bioprinting with Launch of TissuePro: Technical Specifications". 3D Printing Industry. Retrieved 2026-04-01.
- ↑ "TissueLabs launches new TissuePro extrusion-based bioprinter". VoxelMatters. 2025-06-02. Retrieved 2026-04-01.
- ↑ "Conheça as 100 Startups to Watch 2025". Pequenas Empresas & Grandes Negócios. 2025. Retrieved 2026-04-01.
- ↑ Liguori, Gabriel R. (2025). "The Bioartificial Heart: Our Mission to Mars" (PDF). Brazilian Journal of Cardiovascular Surgery. 40 (1). doi:10.21470/1678-9741-2025-0044. PMC 11927143. PMID 40105295.
- provide significant coverage: discuss the subject in detail, not just brief mentions or routine announcements;
- are reliable: from reputable outlets with editorial oversight;
- are independent: not connected to the subject, such as interviews, press releases, the subject's own website, or sponsored content.
Please add references that meet all three of these criteria. If none exist, the subject is not yet suitable for Wikipedia.